In an analysis of the impact and cost-effectiveness of pneumococcal conjugate vaccines (PCV) in preventing disease and deaths in children under five years in 180 countries, the vaccination was most cost-effective in low income regions and Gavi-eligible countries. The average cost per disability adjusted life year (DALY) was $118 in Africa, $853 in Asia, and $16,000 in Europe. PCV introduction throughout Africa would account for nearly 70% of lives saved globally, but requires only 12% of the global investment.
The cost estimates were calculated in international dollars.
Full Citation:
Chen C, Liceras FC, Flasche S et al.. 2019. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Global Health. 7(1).
Title of Article: Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis
Author(s): Chen C, Liceras FC, Flasche S et al.
Publication Year: 2019
Publication Name: Lancet Global Health
Publication Volume: 7(1)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/30554762/
DOI (Digital Object Identifier): 10.1016/S2214-109X(18)30422-4
Topics: Economics & Return on Investment
Disease Vaccines: Pneumococcal disease/PCV/PPSV
Countries: Global